Tailored, Dedicated Support Expedites COVID-19 Vaccine Trial

By Tyler Bye and Patrick McNamara, WCG ThreeWire

As COVID-19 spread around the world, the accompanying lockdowns and travel restrictions brought many challenges for clinical trials. At the same time, there was an urgent effort to develop and test vaccines and therapeutics. These endeavors required enrolling tens of thousands of trial participants as quickly as possible, creating a huge burden on clinical trial sites that were already trying to figure out how to continue work during a global health emergency.

Despite the challenge of a global pandemic, a top five pharmaceutical company developing a COVID-19 vaccine was able to enroll more than 44,000 patients in a clinical trial in just over three months. This record-breaking achievement was made possible thanks to tailored clinical site augmentation that combined the sponsor’s strategy with dedicated, qualified resources focused on what sites needed to recruit, support, and retain patients. Read how more than 30,000 patients came from sites that benefited from tailored clinical site augmentation.